SCHEMBL2215883

SCHEMBL2215883

CCOc1ccc(Br)cc1/C=C/C(=O)O

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.58
HPGD P15428 2/20 0.58
AR P10275 2/20 0.55
KDM4E B2RXH2 8/20 0.54
KMT2A Q03164 3/20 0.54
GAA P10253 2/20 0.54
ALDH1A1 P00352 4/20 0.52
POLB P06746 2/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
MAPT P10636 2/20 0.52
PTGDR2 Q9Y5Y4 1/20 0.51
LMNA P02545 2/20 0.49
GLA P06280 1/20 0.49
MEN1 O00255 2/20 0.48
TNFRSF1A P19438 1/20 0.48
L3MBTL1 Q9Y468 2/20 0.48
CTDSP1 Q9GZU7 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
MAOB P27338 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2215886 1.00 TSHR (0.58) TSHRHPGDARKDM4EKMT2A
SCHEMBL12469444 0.89 HPGD (0.51) TSHRHPGDARKDM4EKMT2A
SCHEMBL2219126 0.88 AR (0.55) TSHRHPGDARKDM4EKMT2A
SCHEMBL1285839 0.83 MAPT (0.67) HPGDARKDM4EKMT2AGAA
SCHEMBL1285840 0.83 MAPT (0.67) HPGDARKDM4EKMT2AGAA
SCHEMBL29935293 0.83 MAPT (0.67) HPGDARKDM4EKMT2AGAA
SCHEMBL21592312 0.82 HPGD (0.52) TSHRHPGDARKDM4EKMT2A
SCHEMBL10638417 0.82 KDM4E (0.54) KDM4EKMT2AGAAALDH1A1POLB
SCHEMBL10638414 0.82 KDM4E (0.54) KDM4EKMT2AGAAALDH1A1POLB
SCHEMBL2167870 0.82 PTGER4 (0.67) KDM4EALDH1A1SMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110177612-A1 Human G Protein-Coupled Receptors and Modulators Thereof for the Treatment of Metabolic-Related Disorders ARENA PHARMACEUTICALS, INC. 2011-07-21 US disclosed
US-7829298-B2 Human G protein-coupled receptors for metabolic-related disorders ARENA PHARMACEUTICALS, INC. (US) 2010-11-09 US disclosed
EP-1474419-B1 AMIDES OF AMINOALKYL-SUBSTITUTED AZETIDINES, PYRROLIDINES, PIPERIDINES AND AZEPANES NOVO NORDISK AS (DK) 2007-09-05 EP disclosed
US-20070079392-A1 Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders ARENA PHARMACEUTICALS, INC. (US) 2007-04-05 US disclosed
US-7101898-B2 For therapy of allergic rhinitis, ulcer or anorexia, diabetes, Alzheimer's disease, narcolepsy or attention deficit disorder NOVO NORDISK A/S (DK) 2006-09-05 US disclosed
US-20050154029-A1 Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders ARENA PHARMACEUTICALS, INC. (US) 2005-07-14 US disclosed
CN-1625554-A Amides of aminoalkyl substituted azetidines, pyrrolidines, piperidines and azepanes NOVO NORDISK AS (DK) 2005-06-08 CN disclosed
US-6902902-B2 Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders ARENA PHARMACEUTICALS, INC. (US) 2005-06-07 US disclosed
US-20050004178-A1 Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders ARENA PHARMACEUTICALS, INC. (US) 2005-01-06 US disclosed
EP-1474419-A1 AMIDES OF AMINOALKYL-SUBSTITUTED AZETIDINES, PYRROLIDINES, PIPERIDINES AND AZEPANES NOVO NORDISK A/S (DK) 2004-11-10 EP disclosed
US-20040142377-A1 Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders ARENA PHARMACEUTICALS, INC. (US) 2004-07-22 US disclosed
US-20040082079-A1 Low affinity screening method GRAFFINITY PHARMACEUTICALS AG. (DE) 2004-04-29 US disclosed
EP-1360489-A1 LOW AFFINITY SCREENING METHOD Graffinity Pharmaceuticals Aktiengesellschaft (DE) 2003-11-12 EP disclosed
US-20030195190-A1 Amides of aminoalkyl-substituted azetidines, pyrrolidines, piperidines and azepanes HIGH POINT PHARMACEUTICALS, LLC 2003-10-16 US disclosed
WO-2003064411-A1 AMIDES OF AMINOALKYL-SUBSTITUTED AZETIDINES, PYRROLIDINES, PIPERIDINES AND AZEPANES NOVO NORDISK A/S (DK) 2003-08-07 WO disclosed
WO-2002063299-A1 LOW AFFINITY SCREENING METHOD GRAFFINITY PHARMACEUTICALS AG (DE) 2002-08-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030195190-A1 Amides of aminoalkyl-substituted azetidines, pyrrolidines, piperidines and azepanes HRH3, HRH2, HRH4 TSHR 363/4885HPGD 863/4885AR 831/4885
US-20050154029-A1 Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders GPR119, ADIPOR2, GCGR TSHR 206/4885HPGD 973/4885AR 501/4885
US-20070079392-A1 Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders GPR119, ADIPOR2, GCGR TSHR 206/4885HPGD 973/4885AR 501/4885
US-20050004178-A1 Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders GPR119, ADIPOR2, GCGR TSHR 206/4885HPGD 973/4885AR 501/4885
US-20040142377-A1 Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders GPR119, ADIPOR2, GCGR TSHR 206/4885HPGD 973/4885AR 501/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.